Maze Therapeutics Inc (NASDAQ: MAZE)’s stock price has plunge by 11.66relation to previous closing price of 11.41. Nevertheless, the company has seen a 13.14% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-29 that SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) — Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today announced that Jason Coloma, Ph.D.
Is It Worth Investing in Maze Therapeutics Inc (NASDAQ: MAZE) Right Now?
Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MAZE is 13.08M, and currently, short sellers hold a 16.40% ratio of that floaft. The average trading volume of MAZE on June 27, 2025 was 168.46K shares.
MAZE’s Market Performance
MAZE stock saw an increase of 13.14% in the past week, with a monthly gain of 13.75% and a quarterly increase of 18.40%. The volatility ratio for the week is 11.43%, and the volatility levels for the last 30 days are 11.03% for Maze Therapeutics Inc (MAZE). The simple moving average for the past 20 days is 3.22% for MAZE’s stock, with a 15.49% simple moving average for the past 200 days.
MAZE Trading at 19.40% from the 50-Day Moving Average
After a stumble in the market that brought MAZE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.06% of loss for the given period.
Stock Fundamentals for MAZE
Current profitability levels for the company are sitting at:
- -44.96 for the present operating margin
- 1.0 for the gross margin
The net margin for Maze Therapeutics Inc stands at -32.36. The total capital return value is set at -0.36.
Based on Maze Therapeutics Inc (MAZE), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -3.71.
Currently, EBITDA for the company is 60.88 million with net debt to EBITDA at 2.44. When we switch over and look at the enterprise to sales, we see a ratio of 115.77. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.10.
Conclusion
In a nutshell, Maze Therapeutics Inc (MAZE) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
